Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Carl Dambkowski Sells 3,860 Shares

Apogee Therapeutics, Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 3,860 shares of the firm’s stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $36.22, for a total value of $139,809.20. Following the completion of the sale, the insider now owns 247,173 shares of the company’s stock, valued at approximately $8,952,606.06. This represents a 1.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, March 5th, Carl Dambkowski sold 1,590 shares of Apogee Therapeutics stock. The shares were sold at an average price of $30.48, for a total transaction of $48,463.20.
• On Wednesday, February 5th, Carl Dambkowski sold 3,520 shares of Apogee Therapeutics stock. The stock was sold at an average price of $40.69, for a total transaction of $143,228.80.

Apogee Therapeutics Trading Down 7.6 %

Shares of Apogee Therapeutics stock traded down $2.67 on Friday, hitting $32.32. 1,079,651 shares of the company traded hands, compared to its average volume of 491,236. The company has a market cap of $1.46 billion, a PE ratio of -13.36 and a beta of 1.72. The stock’s 50 day moving average price is $37.21 and its 200-day moving average price is $45.49. Apogee Therapeutics, Inc. has a 52 week low of $29.10 and a 52 week high of $63.50.

Apogee Therapeutics (NASDAQ:APGE) last issued its earnings results on Monday, March 3rd. The company reported ($1.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.25). As a group, research analysts anticipate that Apogee Therapeutics, Inc. will post -3.09 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have issued reports on APGE. Wedbush restated an “outperform” rating and set a $90.00 target price on shares of Apogee Therapeutics in a research report on Tuesday, March 11th. Guggenheim restated a “buy” rating on shares of Apogee Therapeutics in a report on Monday, February 10th. Finally, Citigroup assumed coverage on Apogee Therapeutics in a research note on Thursday, March 13th. They issued a “buy” rating and a $95.00 target price on the stock. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Apogee Therapeutics has an average rating of “Buy” and an average price target of $92.17.

Institutional Trading of Apogee Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in APGE. Intech Investment Management LLC purchased a new position in Apogee Therapeutics during the 3rd quarter valued at about $300,000. Charles Schwab Investment Management Inc. boosted its stake in shares of Apogee Therapeutics by 17.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 280,428 shares of the company’s stock valued at $16,472,000 after purchasing an additional 41,686 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Apogee Therapeutics during the third quarter valued at approximately $71,000. Janus Henderson Group PLC raised its stake in Apogee Therapeutics by 4,018.9% in the third quarter. Janus Henderson Group PLC now owns 469,557 shares of the company’s stock worth $27,586,000 after buying an additional 458,157 shares in the last quarter. Finally, Point72 Asset Management L.P. lifted its holdings in Apogee Therapeutics by 162.7% during the third quarter. Point72 Asset Management L.P. now owns 707,268 shares of the company’s stock worth $41,545,000 after buying an additional 438,036 shares during the period. 79.04% of the stock is currently owned by institutional investors.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.